Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Ly M Nguyen"'
Autor:
Ignacio Garrido-Laguna, David S Hong, Filip Janku, Ly M Nguyen, Gerald S Falchook, Siqing Fu, Jenifer J Wheler, Rajyalakshmi Luthra, Aung Naing, Xuemei Wang, Razelle Kurzrock
Publikováno v:
PLoS ONE, Vol 7, Iss 5, p e38033 (2012)
To evaluate clinicopathologic and molecular features of patients with metastatic colorectal cancer (mCRC) and their outcomes in early-phase trials using pathway-targeting agents.We analyzed characteristics of 238 patients with mCRC referred to the ph
Externí odkaz:
https://doaj.org/article/1d87a5c8f302478a98b8e914f4f86065
Autor:
John Nemunaitis, James P. O'Brien, Pallavi Sachdev, Corina Andresen, Cynthia Bedell, Jennifer Mink, Min Ren, Robert Shumaker, Lucy Xu, Goldy C. George, Ly M. Nguyen, Michael A. Davies, Kevin B. Kim, Siqing Fu, Gerald S. Falchook, Aung Naing, Jennifer J. Wheler, Razelle Kurzrock, David S. Hong
Supplementary Tables S1 and S2. Supplementary Table 1. Univariate Cox proportional hazard model analysis using baseline and change in levels of biomarkers with PFS Supplementary Table 2. Multivariate Cox proportional hazard model analysis using basel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f763894bc770dba6ac95ef69cfb9c40
https://doi.org/10.1158/1078-0432.22458195
https://doi.org/10.1158/1078-0432.22458195
Autor:
John Nemunaitis, James P. O'Brien, Pallavi Sachdev, Corina Andresen, Cynthia Bedell, Jennifer Mink, Min Ren, Robert Shumaker, Lucy Xu, Goldy C. George, Ly M. Nguyen, Michael A. Davies, Kevin B. Kim, Siqing Fu, Gerald S. Falchook, Aung Naing, Jennifer J. Wheler, Razelle Kurzrock, David S. Hong
Purpose: This “3+3” phase I study evaluated the safety, biologic, and clinical activity of lenvatinib, an oral multikinase inhibitor, in patients with solid tumors.Experimental Design: Ascending doses of lenvatinib were administered per os twice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3839d647413c4a841ebad871c41ed31e
https://doi.org/10.1158/1078-0432.c.6523866.v1
https://doi.org/10.1158/1078-0432.c.6523866.v1
Autor:
David S. Hong, Michael A. Curran, Kimal Rajapakshe, Ly M. Nguyen, Di Nguyen, Hira Zain, Elizabeth Sumner, Funda Meric-Bernstam, JoAnn Lim, Thomas F. Wilson, Eric T. Williams, Jack P. Higgins, Cristian Coarfa, Priya Bhosale, Vivek Subbiah, Timothy A. Yap, Ecaterina E. Dumbrava, Siqing Fu, Shubham Pant, Jordi Rodon, Daniel Karp, Sarina Piha-Paul, Coline A. Couillault, Priyamvada Jayaprakash, Aparna Hegde
Compilation of supplemental tables and figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1b735def399b806d88f9c72e98f39df
https://doi.org/10.1158/1078-0432.22479855.v1
https://doi.org/10.1158/1078-0432.22479855.v1
Autor:
David S. Hong, Michael A. Curran, Kimal Rajapakshe, Ly M. Nguyen, Di Nguyen, Hira Zain, Elizabeth Sumner, Funda Meric-Bernstam, JoAnn Lim, Thomas F. Wilson, Eric T. Williams, Jack P. Higgins, Cristian Coarfa, Priya Bhosale, Vivek Subbiah, Timothy A. Yap, Ecaterina E. Dumbrava, Siqing Fu, Shubham Pant, Jordi Rodon, Daniel Karp, Sarina Piha-Paul, Coline A. Couillault, Priyamvada Jayaprakash, Aparna Hegde
Purpose:As hypoxia can mediate resistance to immunotherapy, we investigated the safety, tolerability, and efficacy of combining evofosfamide, a prodrug that alleviates hypoxia, with ipilimumab, an immune checkpoint inhibitor, in immunologically “co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86672c133a9002c5ca5f7cc49d4f510c
https://doi.org/10.1158/1078-0432.c.6530310
https://doi.org/10.1158/1078-0432.c.6530310
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Recombinant human erythropoietin (rHuEPO) is used effectively in the treatment of various anemic disorders. Belgrade rat is a useful animal model of anemia caused by defect in iron utilization. The objective of the present study was to investigate th
Externí odkaz:
https://doaj.org/article/84c2768ec1d048308aa892479a381984
Autor:
Mianen Sun, Ly M. Nguyen, Elsa J. Brown, David S. Hong, Shumei Kato, Siqing Fu, Timothy A. Yap, Sarina Anne Piha-Paul, Vivek Subbiah, Daniel D. Karp, Jacob J. Adashek
Publikováno v:
Investigational New Drugs. 40:99-105
Background. Preclinical studies have shown that the combined inhibition of EGFR and NF-kB pathways to target the RalB/TBK1 pathway led to synergistic antitumor activity. Based on this rationale, we conducted a Phase I dose-escalation study combining
Autor:
Jordi Rodon, Joann Lim, Elizabeth A. Sumner, Hira Zain, Di Nguyen, Jack P. Higgins, Vivek Subbiah, Funda Meric-Bernstam, Eric T Williams, Coline Agnes Couillault, Siqing Fu, Timothy A. Yap, Kimal Rajapakshe, Aparna Hegde, Sarina Anne Piha-Paul, Shubham Pant, Michael A. Curran, Priya Bhosale, Priyamvada Jayaprakash, David S. Hong, Thomas F. Wilson, Daniel D. Karp, Ecaterina Ileana Dumbrava, Ly M. Nguyen, Cristian Coarfa
Publikováno v:
Clin Cancer Res
Purpose: As hypoxia can mediate resistance to immunotherapy, we investigated the safety, tolerability, and efficacy of combining evofosfamide, a prodrug that alleviates hypoxia, with ipilimumab, an immune checkpoint inhibitor, in immunologically “c
Autor:
Suzanne F. Jones, Ji Lin, Howard A. Burris, Ly M. Nguyen, Lisa Golden, Aimee Bence Lin, David S. Hong, Johanna C. Bendell, Todd M. Bauer, Aung Naing, Razelle Kurzrock, Filip Janku, Jeffrey R. Infante, Sarina Anne Piha-Paul, Faye M. Johnson, Scott M. Hynes
Publikováno v:
Journal of Clinical Oncology. 34:1764-1771
Purpose The primary objective was to determine safety, toxicity, and a recommended phase II dose regimen of LY2606368, an inhibitor of checkpoint kinase 1, as monotherapy. Patients and Methods This phase I, nonrandomized, open-label, dose-escalation
Autor:
Michael A. Davies, Corina Andresen, Jennifer J. Wheler, Goldy C. George, Lucy Xu, Razelle Kurzrock, Min Ren, Gerald Steven Falchook, Kevin B. Kim, Siqing Fu, James P. O'Brien, David S. Hong, John Nemunaitis, Jennifer Mink, Robert Shumaker, Cynthia Bedell, Pallavi Sachdev, Ly M. Nguyen, Aung Naing
Publikováno v:
Clinical Cancer Research. 21:4801-4810
Purpose: This “3+3” phase I study evaluated the safety, biologic, and clinical activity of lenvatinib, an oral multikinase inhibitor, in patients with solid tumors. Experimental Design: Ascending doses of lenvatinib were administered per os twice